NCT06141889

Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

A Phase 1, Single-dose, Open-label, Randomized Crossover and Multiple-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Azelaprag in Older Adult Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: BioAge Labs, Inc. · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Accepted

Summary

This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers.

Detailed description

This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers. The study will enroll approximately 16 participants.

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	Azelaprag	oral, apelin receptor (APJ) agonist

Timeline

• Start date: 2023-11-17
• Primary completion: 2024-01-26
• Completion: 2024-02-02
• First posted: 2023-11-21
• Last updated: 2024-02-23

Locations

1 site across 1 country: New Zealand